Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo‐controlled trial in North East Asia
Open Access
- 23 December 2023
- journal article
- research article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (1)
Abstract
Aim: This post hoc analysis evaluated the efficacy and safety of intravenous belimumab 10 mg/kg in the South Korean subgroup of patients with systemic lupus erythematosus (SLE) enrolled in the North East Asia (NEA) study (GSK Study BEL113750; NCT01345253).Methods: NEA was a double‐blind, placebo‐controlled, randomized Phase 3 trial. Patients with active, autoantibody‐positive SLE were randomized 2:1 to belimumab or placebo plus standard therapy administered on Days 0, 14, and 28, and then every 28 days up to Week 48. The primary efficacy endpoint in this analysis was SLE Responder Index 4 (SRI‐4) response rate at Week 52, defined as the proportion of patients achieving a ≥4‐point reduction in Safety of Estrogens in Lupus Erythematosus National Assessment‐SLE Disease Activity Index (SELENA‐SLEDAI) score, no worsening (n = 35/66, 53.0% vs. n = 8/34, 23.5%; odds ratio [OR; 95% confidence interval (CI)]: 3.67 [1.45, 9.28]; p = .0061). The proportion of patients experiencing ≥1 adverse event was similar between groups (belimumab: n = 60/66, 90.9% vs. placebo: n = 31/34, 91.2%). No new safety signals emerged in this subgroup analysis.Conclusion: Belimumab was efficacious for the treatment of SLE and well tolerated among the South Korean subgroup of patients from the NEA study.Keywords
Funding Information
- GlaxoSmithKline
This publication has 28 references indexed in Scilit:
- Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception CohortAnnals of the Rheumatic Diseases, 2015
- Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus CohortLupus Science & Medicine, 2015
- Prevalence and incidence of systemic lupus erythematosus in South KoreaRheumatology International, 2013
- Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomesLupus, 2013
- Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus ClinicLupus, 2013
- Predictors of organ damage in systemic lupus erythematosus: The Hopkins Lupus CohortArthritis & Rheumatism, 2012
- Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of responseAnnals of the Rheumatic Diseases, 2012
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis & Rheumatism, 2011
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulatorArthritis & Rheumatism, 2003